Idera Pharmaceuticals Inc. (IDRA) announced positive interim results from a Phase 1 clinical trial of IMO-2125 in patients with chronic hepatitis C virus infection or HCV.
IMO-2125 is an agonist of Toll-like Receptor 9 that Idera designed to treat HCV by inducing endogenous interferon-alpha and other Th1-type cytokines and chemokines.
The company said that, in this 4-week trial, IMO-2125 was well tolerated and induced dose-dependent increases in endogenous interferon-alpha and other cytokines. Also, IMO-2125 demonstrated a treatment-related decrease in viral load at escalating dose levels.
Based on these data, the company noted that it is extending the trial to a fifth dose level and beginning to recruit patients in this cohort. Idera Pharma intends to use the ongoing clinical trial results to guide its strategy for further development of IMO-2125 for the null responder HCV patient population.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.